CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 94,378 shares at an average $70.35 ($6,639,523)
- 4 Open-market sale COO and Secretary sold 10,000 shares at an average $64.55 ($645,500)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Grant or award Director acquired 2,074 shares (grant or award)
- 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
- 4 Other disposition Director disposed of 1,000,000 shares (other)
- 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
- 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
- 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
- 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
- 4 Open-market sale President and CEO sold 18,333 shares at an average $61.40 ($1,125,648)
- 4 Open-market sale Director sold 1,666 shares at an average $65.37 ($108,911)
- 4 Open-market sale Director sold 46,763 shares at an average $60.11 ($2,811,048)
- 4 Open-market sale COO and Secretary sold 10,000 shares at an average $55.49 ($554,864)
Page 12 of 22 · 436 filings